FDA feedback provides clear clinical path for NEO-001, the first obesity drug therapy focused on neuropharmacological and behavioral changes for sustainable weight loss Company plans to file an IND application for a Phase 1/2 clinical study anticipated to start in H1'2022 VANCOUVER, BC / ACCESSWIRE / November 23, 2021
Full Story >>
Vote
+10